Tacrolimus and cyclosporine A inhibit allostimulatory capacity and cytokine production of human myeloid dendritic cells
| dc.contributor.author | Szabo, Gyongyi | |
| dc.contributor.author | Gavala, C. | |
| dc.contributor.author | Mandrekar, Pranoti | |
| dc.date | 2022-08-11T08:08:37.000 | |
| dc.date.accessioned | 2022-08-23T16:01:22Z | |
| dc.date.available | 2022-08-23T16:01:22Z | |
| dc.date.issued | 2001-08-29 | |
| dc.date.submitted | 2010-04-21 | |
| dc.identifier.citation | J Investig Med. 2001 Sep;49(5):442-9. | |
| dc.identifier.issn | 1081-5589 (Linking) | |
| dc.identifier.pmid | 11523700 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14038/31105 | |
| dc.description.abstract | Myeloid dendritic cells (DCs) are pivotal in the recognition of alloantigens and, therefore, in the induction of allograft rejection. Induction of alloreactive T cell proliferation by myeloid DCs depends on the maturation of DCs, the expression of costimulatory molecules, and the cytokine environment. This study investigated the effects of tacrolimus and cyclosporine A (CsA) on DC maturation and allostimulatory capacity. Myeloid DCs were propagated from normal blood monocytes with interleukin (IL) 4 and GM-CSF for 7 days in the presence or absence of tacrolimus (FK506; 10 nM) or CsA (1 microg/mL). Exposure of DCs during maturation to tacrolimus or CsA resulted in no significant change in the expression of DC phenotypic markers, including CD80, CD86, and HLA Class I and II antigens determined by flow cytometry. T cell proliferation in one-way, mixed-leukocyte reaction experiments revealed a decreased allostimulatory capacity of DCs that matured in the presence of tacrolimus or CsA compared with untreated controls (P<0.02). Production of inflammatory cytokines, tumor necrosis factor alpha (P<0.04) and IL-12 (P<0.04) in response to lipopolysaccharide (1 microg/mL) or staphylococcal enterotoxin B (1 microg/mL) induction was significantly reduced in DCs exposed to tacrolimus or CsA during maturation. In contrast, production of the immuninhibitory cytokine IL-10 was not decreased in tacrolimus- or CsA-treated DCs. These results suggest that tacrolimus and CsA inhibit the allostimulatory capacity of in vitro-generated myeloid DCs without significant effects on DC phenotypic maturation. Decreased production of IL-12 and tumor necrosis factor alpha, but not of IL-10, is likely to contribute to the impaired accessory-cell function of tacrolimus- and CsA-treated DCs. Thus, tacrolimus and CsA can inhibit recognition of alloantigens by decreasing the accessory-cell capacity of monocyte-derived myeloid DCs. | |
| dc.language.iso | en_US | |
| dc.relation | <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=11523700&dopt=Abstract">Link to Article in PubMed</a> | |
| dc.relation.url | http://dx.doi.org/10.2310/6650.2001.33789 | |
| dc.subject | Cyclosporine | |
| dc.subject | Cytokines | |
| dc.subject | Dendritic Cells | |
| dc.subject | Humans | |
| dc.subject | Immunosuppressive Agents | |
| dc.subject | Isoantigens | |
| dc.subject | *Lymphocyte Activation | |
| dc.subject | Monocytes | |
| dc.subject | T-Lymphocytes | |
| dc.subject | Tacrolimus | |
| dc.subject | Gastroenterology | |
| dc.subject | Immunology and Infectious Disease | |
| dc.title | Tacrolimus and cyclosporine A inhibit allostimulatory capacity and cytokine production of human myeloid dendritic cells | |
| dc.type | Journal Article | |
| dc.source.journaltitle | Journal of investigative medicine : the official publication of the American Federation for Clinical Research | |
| dc.source.volume | 49 | |
| dc.source.issue | 5 | |
| dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/gastroenterology_pp/31 | |
| dc.identifier.contextkey | 1282326 | |
| html.description.abstract | <p>Myeloid dendritic cells (DCs) are pivotal in the recognition of alloantigens and, therefore, in the induction of allograft rejection. Induction of alloreactive T cell proliferation by myeloid DCs depends on the maturation of DCs, the expression of costimulatory molecules, and the cytokine environment. This study investigated the effects of tacrolimus and cyclosporine A (CsA) on DC maturation and allostimulatory capacity. Myeloid DCs were propagated from normal blood monocytes with interleukin (IL) 4 and GM-CSF for 7 days in the presence or absence of tacrolimus (FK506; 10 nM) or CsA (1 microg/mL). Exposure of DCs during maturation to tacrolimus or CsA resulted in no significant change in the expression of DC phenotypic markers, including CD80, CD86, and HLA Class I and II antigens determined by flow cytometry. T cell proliferation in one-way, mixed-leukocyte reaction experiments revealed a decreased allostimulatory capacity of DCs that matured in the presence of tacrolimus or CsA compared with untreated controls (P<0.02). Production of inflammatory cytokines, tumor necrosis factor alpha (P<0.04) and IL-12 (P<0.04) in response to lipopolysaccharide (1 microg/mL) or staphylococcal enterotoxin B (1 microg/mL) induction was significantly reduced in DCs exposed to tacrolimus or CsA during maturation. In contrast, production of the immuninhibitory cytokine IL-10 was not decreased in tacrolimus- or CsA-treated DCs. These results suggest that tacrolimus and CsA inhibit the allostimulatory capacity of in vitro-generated myeloid DCs without significant effects on DC phenotypic maturation. Decreased production of IL-12 and tumor necrosis factor alpha, but not of IL-10, is likely to contribute to the impaired accessory-cell function of tacrolimus- and CsA-treated DCs. Thus, tacrolimus and CsA can inhibit recognition of alloantigens by decreasing the accessory-cell capacity of monocyte-derived myeloid DCs.</p> | |
| dc.identifier.submissionpath | gastroenterology_pp/31 | |
| dc.contributor.department | Department of Medicine, Rheumatology Division | |
| dc.contributor.department | Department of Medicine, Division of Gastroenterology | |
| dc.source.pages | 442-9 |